Jeyanthi Suppiah and Zainah Saat (2015). Efficacy of tenofovir as first-line antiviral therapy in chronic hepatitis B infection. Innovative Journal of Medical and Health Science 5: 73-78
To date, various antiviral therapy options are available in treatment of chronic hepatitis B (CHB). Choosing the right drug according to patients’ profile is utmost crucial for optimal response, recovery and prevention of drug resistance. Tenofovir (TDF) is an approved first-line drug treatment for CHB. Several studies have reported on the safety and efficaciousness of TDF in treating CHB patients and achieving improvement. This narrative review article aimed to compile study evidences that highlighted the effectiveness of TDF as antiviral therapy in CHB patients. From the analysis done, it can be summarized that patients who have been undergoing TDF monotherapy or switched to TDF after other antiviral therapy had profound HBV DNA suppression level, no resistance detected and improved health condition. Based on this, TDF is strongly recommended to be continued as first-line treatment for CHB patients.